Dual first-line therapy for treatment-naive patients with advanced RCC is with anti-programmed death-ligand (PD-L1) immunotherapy and tyrosine kinase inhibitors (TKI) [2]. The gene discussed is CD274; the disease is renal cell carcinoma.